What is Transcode Therapeutics Inc (RNAZ) stock price today?

Transcode Therapeutics Inc (RNAZ) currently trades at $8.01 per share. The stock has a market capitalization of $7.75M and a P/E ratio of —x.

Is RNAZ stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Transcode Therapeutics Inc has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -26.99.

Is Transcode Therapeutics Inc financially healthy?

Transcode Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -26.99 places it in the distress.

RNAZ

Transcode Therapeutics Inc

NASDAQ: RNAZ · HEALTHCARE · BIOTECHNOLOGY

$8.01

-4.64% today

Updated 2026-04-30

Market cap

$7.75M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-52.59

Dividend yield

—

52W range

$6 – $22

Volume

0.0M

Market cap

$7.75M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-52.59

Dividend yield

—

52W range

$6 – $22

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.3

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-27.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$10.00

+24.84%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -26.99 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-8.15M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-17.56M	$-18.55M	$-16.75M	$-34.66M	$-13.44M
EPS	—	—	—	—	$-52.59
Free cash flow	$-15.86M	$-18.11M	$-13.36M	$-19.52M	$-8.15M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RNAZ	$7.75M	26	4.3	3.0	5.0	4.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Transcode Therapeutics Inc trades at $8.01. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -26.99, it sits in the distress.

Frequently asked questions

What is Transcode Therapeutics Inc's stock price?

Transcode Therapeutics Inc (RNAZ) trades at $8.01.

Is Transcode Therapeutics Inc overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Transcode Therapeutics Inc (RNAZ)?

The analyst target price is $10.00, representing +24.8% upside from the current price of $8.01.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-26.99 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.transcodetherapeutics.com

Quick metrics

P/S ratio—

ROE-46.30%

Beta1.50

50D MA$9.13

200D MA$9.94

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RNAZ vs LLY →RNAZ vs JNJ →RNAZ vs ABBV →Stock screener →